Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 197.62

+0.1%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (9953)	10/22/1997 2:16:00 AM
From: Vector1	Read Replies (1) of 32384

Andy, when you are in an acrobat document click on tools and then click on select text. You will then be able to highlight whatever you want to copy. Interesting that the molecule LGND gets from LLY has not been selected yet. I keep trying to figure out how this came about. My best guess is LGND was not prepared to make a decision so they built an incentive into the contract. If you assume that Tagretin is a potential blockbuster for diabetes the additional 1.5% royalty could be meaningful. 15%- 16.5% is a hell of a good royalty rate and typical of products significantly further in development. Remember LLY is paying for most of the development costs and all the manufacturing and marketing/sales costs. If Tagretin is sucessful in clinicals it could easily be a billion plus product. 10% (after 33% payment to AGN) is real money. In addition to a potential new rev source in 99 from LLY the deal will allow LGND to become profitable because the milestone payments which will be booked as revenue will offset much of he R&D. My suggestion is to fasten your seatbelts and sitback and enjoy the ride. V1 V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next